KalVista Pharmaceuticals (KALV) Tops Q2 EPS by 2c
Tweet
Share
E-mailGet Alerts KALV Hot Sheet
Join SI Premium – FREE
KalVista Pharmaceuticals (NASDAQ: KALV) reported Q2 EPS of ($0.91), $0.02 better than the analyst estimate of ($0.93).
For earnings history and earnings-related data on KalVista Pharmaceuticals (KALV) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
- Texas Capital Securities Reiterates Buy Rating on Texas Pacific Land Trust (TPL)
- Pelican Way Research shorts Hyliion Holdings (HYLN) on VFG deal concerns
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
